Please use this identifier to cite or link to this item:
Title: Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse.
Authors: Sale, S
Tunstall, RG
Ruparelia, KC
Butler, PC
Potter, GA
Steward, WP
Gescher, AJ
First Published: Nov-2006
Citation: INVEST NEW DRUGS, 2006, 24 (6), pp. 459-464
Abstract: DMU-135 (3,4-Methylenedioxy-3',4',5'-trimethoxy chalcone) is a novel anticancer prodrug designed to be activated into a potent tyrosine kinase inhibitor by the tumour selective enzyme activity of the cytochrome P450 enzyme CYP1B1. CYP1B1 is selectively expressed in a wide variety of tumours including colon. The hypothesis was tested that DMU-135 would inhibit Apc(Min/+) mouse gastrointestinal adenoma formation. From 4-18 weeks of age animals received DMU-135 (0.2% w:w) in AIN93G diet. DMU-135 was well tolerated, induced no systemic side-effects and reduced adenoma multiplicity by 46 +/- 18.3% compared to controls (p < 0.001). Further characterisation of this promising chemopreventive agent is required.
DOI Link: 10.1007/s10637-006-5947-0
ISSN: 0167-6997
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.